Transitioning From Immunosuppressants to Dupilumab in Pediatric Atopic Dermatitis

被引：4

作者：

Ludwig, Catherine M. ^{[1
]}

Hsiao, Jennifer L. ^{[2
]}

Lio, Peter A. ^{[3
,4
]}

Shi, Vivian Y. ^{[5
]}

机构：

[1] Univ Illinois, Coll Med, Chicago, IL 60680 USA

[2] Univ Calif Los Angeles, Div Dermatol, Dept Med, Los Angeles, CA USA

[3] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL USA

[4] Med Dermatol Associates Chicago, Chicago, IL USA

[5] Univ Arkansas Med Sci, Dept Dermatol, Little Rock, AR USA

来源：

DERMATITIS | 2021年 / 32卷 / 1S期

关键词：

GUIDELINES; ADULTS;

D O I：

10.1097/DER.0000000000000690

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Dupilumab has recently been approved by the Food and Drug Administration for use for treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years. It presents a novel treatment option with a favorable safety profile for patients who are currently reliant on immunosuppressants, including cyclosporine A, methotrexate, and mycophenolate mofetil. Particularly during the current COVID-19 pandemic, immunosuppression should be avoided to retain intrinsic antiviral immunity. Transitioning to dupilumab should be executed strategically-tapering immunosuppressants and minimizing risk of flare by overlapping with the biologic. Herein, we use results of outcome measurements from LIBERTY AD ADOL and LIBERTY AD PEDS trials of dupilumab in adolescents aged 12 to 18 years and children aged 6 to 11 years, respectively, to propose a schematic for an 8-week transition between medications.

引用

页码：S4 / S7

页数：4

共 19 条

[1] Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis [J].